The prevalence of cancer and other diseases with epigenetic modification will fuel Epigenetics market growth, the global epigenetics market is expected to reach $12.8 Billion by 2020.

By product, Epigenetic reagents was the largest market valued at over USD 1.72 billion in 2016 owing to the increasing amount of R&D investments and high consumption rates. Kits are expected to gain rapid growth in demand due to the increasing need of rapid and accurate detection techniques; additionally, new upgraded kits for easy and efficient detection of biomarkers will foster the growth.

In terms of technology, DNA methylation was the largest technology sect accounting for over 50% revenue in 2016. The introduction of technological advancement such as Methylation Sensitive PCR (MSP) and rapid adoption of these products to improve diagnostics efficiency are some factors attributing for its largest share.

On the basis of application market, oncology was the largest application market, with revenue valued at over USD 3.07 billion. Growing prevalence of cancer with epigenetic modification base and strong product pipeline are some factors attributing to its market position.

Geographically, North America was witnessed to be the largest regional epigenetics market accounting for over 41.0% of the overall revenue, Asia is expected to be fastest growing region with a CAGR of 12.4% over 2016-2020.

World leading players of the epigenetics market include Illumina, Abcam, Diagenode, Thermo Fisher Scientific, Merck, Zymo research, Qiagen, CellCentric Ltd, Chroma Therapeutics Ltd, Eisai Co. Ltd, Novartis International AG, Oncolys Biopharma Inc., Syndax Pharmaceuticals, Inc., Valirx Plc and Sigma-Aldrich Corporation.

The prevalence of cancer and other diseases with epigenetic modification will fuel Epigenetics market growth, the global epigenetics market is expected to reach $12.8 Billion by 2020.

By product, Epigenetic reagents was the largest market valued at over USD 1.72 billion in 2016 owing to the increasing amount of R&D investments and high consumption rates. Kits are expected to gain rapid growth in demand due to the increasing need of rapid and accurate detection techniques; additionally, new upgraded kits for easy and efficient detection of biomarkers will foster the growth.

In terms of technology, DNA methylation was the largest technology sect accounting for over 50% revenue in 2016. The introduction of technological advancement such as Methylation Sensitive PCR (MSP) and rapid adoption of these products to improve diagnostics efficiency are some factors attributing for its largest share.

On the basis of application market, oncology was the largest application market, with revenue valued at over USD 3.07 billion. Growing prevalence of cancer with epigenetic modification base and strong product pipeline are some factors attributing to its market position.

Geographically, North America was witnessed to be the largest regional epigenetics market accounting for over 41.0% of the overall revenue, Asia is expected to be fastest growing region with a CAGR of 12.4% over 2016-2020.

World leading players of the epigenetics market include Illumina, Abcam, Diagenode, Thermo Fisher Scientific, Merck, Zymo research, Qiagen, CellCentric Ltd, Chroma Therapeutics Ltd, Eisai Co. Ltd, Novartis International AG, Oncolys Biopharma Inc., Syndax Pharmaceuticals, Inc., Valirx Plc and Sigma-Aldrich Corporation.

Read Full Report: http://www.gosreports.com/global-epigenetics-market-research-report-2016/

Joanna | Executive – International Business and partner Relations
E-mail: [email protected] | Tel: 510-400-8520
Web: www.gosreports.com
________________________________________________